Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Few drugs in hepatology have shaped a field as profoundly—and generated as much regulatory controversy—as obeticholic acid (OCA) [1, 2]. The POISE open-label extension (OLE) study by Bowlus et al. [3] provides the longest prospective follow-up available for a second-line therapy in primary biliary cholangitis (PBC), with up to 6 years of OCA exposure.
During the past two decades, several studies showed reduced rates of hepatocellular carcinoma recurrence in patients with HCV-related cirrhosis after interferon-based antiviral therapies respect to untreated controls, even without reaching viral clearance. The recent development of new all-oral regimens with direct-acting antivirals has radically improved the therapeutic management of hepatitis C.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
